Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C9H12BNO4 |
| Molecular Weight | 208.2088 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CC1=CC=C(C=C1)[10B](O)O)C(O)=O
InChI
InChIKey=NFIVJOSXJDORSP-ULMHTEDTSA-N
InChI=1S/C9H12BNO4/c11-8(9(12)13)5-6-1-3-7(4-2-6)10(14)15/h1-4,8,14-15H,5,11H2,(H,12,13)/t8-/m0/s1/i10-1
| Molecular Formula | C9H12BNO4 |
| Molecular Weight | 208.2088 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Boronophenylalanine B-10 (also known as BPA), a boron delivery agent, is used in boron-neutron capture therapy (BNCT) for metastatic melanomas and other tumors. BNCT is a therapeutic modality for malignant tumors using the nuclear capture and fission reactions that occur when boron-10 (10B) is irradiated with neutron beams. This reaction, in theory, only kills 10B-containing cells because the destructive effect of the alpha particles and lithium nuclei, which are produced by the reaction, is limited to the immediate vicinity of the reaction, approximately one cell diameter. Boronophenylalanine is localized to cells through transporter-mediated mechanisms. Aromatic amino acid transporters, ATB0,+, as well as LAT1 contribute significantly to the tumor accumulation of BPA at clinical dose.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Biodistribution of boronophenylalanine in patients with glioblastoma multiforme: boron concentration correlates with tumor cellularity. | 1998 Feb |
|
| Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB0,+, LAT1 and LAT2. | 2015 Mar |
Sample Use Guides
Boron-10 (10B) concentrations were measured in 107 surgical samples from 15 patients with glioblastoma multiforme who were infused with 95 atom% 10B-enriched p-boronophenylalanine (BPA) intravenously for 2 h just prior to surgery at doses ranging from 98 to 290 mg BPA/kg body weight.
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:59:54 GMT 2023
by
admin
on
Sat Dec 16 16:59:54 GMT 2023
|
| Record UNII |
963AI80S1B
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
25033700
Created by
admin on Sat Dec 16 16:59:54 GMT 2023 , Edited by admin on Sat Dec 16 16:59:54 GMT 2023
|
PRIMARY | |||
|
DTXSID30230833
Created by
admin on Sat Dec 16 16:59:54 GMT 2023 , Edited by admin on Sat Dec 16 16:59:54 GMT 2023
|
PRIMARY | |||
|
C171879
Created by
admin on Sat Dec 16 16:59:54 GMT 2023 , Edited by admin on Sat Dec 16 16:59:54 GMT 2023
|
PRIMARY | |||
|
100000181136
Created by
admin on Sat Dec 16 16:59:54 GMT 2023 , Edited by admin on Sat Dec 16 16:59:54 GMT 2023
|
PRIMARY | |||
|
10694
Created by
admin on Sat Dec 16 16:59:54 GMT 2023 , Edited by admin on Sat Dec 16 16:59:54 GMT 2023
|
PRIMARY | |||
|
963AI80S1B
Created by
admin on Sat Dec 16 16:59:54 GMT 2023 , Edited by admin on Sat Dec 16 16:59:54 GMT 2023
|
PRIMARY | |||
|
80994-59-8
Created by
admin on Sat Dec 16 16:59:54 GMT 2023 , Edited by admin on Sat Dec 16 16:59:54 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
NON-LABELED -> LABELED |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|
